After a six-week delay, the US Food and Drug Administration has approved Novavax’s Covid-19 vaccine, according to a letter ...

The agency narrowed who can get the shot and added new study requirements that could cost the company tens of millions.

President Donald Trump's tax cut and spending bill faces a critical stress test on Wednesday as Republicans in the U.S. House ...

The U.S. Food and Drug Administration approved Novavax's COVIDd-19 vaccine with age restrictions after a six-week delay.

The FDA has approved Nuvaxovid to prevent COVID-19 in adults 65 years and older and high-risk individuals 12 through 64 years ...

Novavax can finally breathe a sigh of relief – at least a small one. The Food and Drug Administration approved the company's ...

Novavax shares surged more than 17% before the bell on Monday, following the long-delayed approval of its COVID-19 vaccine ...

Novavax Inc. jumped after US regulators fully approved its Covid vaccine, easing investors’ concerns after the clearance was ...

Novavax (NVAX) shares climbed more than 17% premarket on Monday after the long-delayed approval of its COVID-19 vaccine from ...

At long last, Novavax has secured a full FDA approval for its protein-based COVID-19 vaccine, though not in the broad ...

The Food and Drug Administration says it has decided to continue approving COVID-19 vaccine updates for seniors and others at ...

Previously granted Emergency Use Authorization, Nuvaxovid is now available for individuals over 12 years of age.